These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15274674)

  • 61. Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial.
    Kongkam P; Khongkha W; Lopimpisuth C; Chumsri C; Kosarussawadee P; Phutrakool P; Khamsai S; Sawanyawisuth K; Sura T; Phisalprapa P; Buamahakul T; Siwamogsatham S; Angsusing J; Poonniam P; Wanaratna K; Teerachaisakul M; Pongpirul K
    BMJ Evid Based Med; 2023 Nov; 28(6):399-406. PubMed ID: 37696679
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
    Yongwatana K; Harinwan K; Chirapongsathorn S; Opuchar K; Sanpajit T; Piyanirun W; Puttapitakpong C
    J Gastroenterol Hepatol; 2022 Feb; 37(2):335-341. PubMed ID: 34652861
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Approaches to uninvestigated dyspepsia.
    Jones RH
    Gut; 2002 May; 50 Suppl 4(Suppl 4):iv42-6. PubMed ID: 11953347
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Primperan and the dyspeptic syndrome].
    Vincentelli JM
    Ann Gastroenterol Hepatol (Paris); 1985 May; 21(2 Pt 2):27-8. PubMed ID: 4037710
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The multi-crossover model for classifying patients as responders to a given treatment.
    Larsen S; Farup P; Flaten O; Osnes M
    Scand J Gastroenterol; 1991 Jul; 26(7):763-70. PubMed ID: 1896820
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Functional dyspepsia: are there any rational grounds for therapy selection?
    Sáinz Samitier R
    Rev Esp Enferm Dig; 2001 May; 93(5):273-80. PubMed ID: 11488105
    [No Abstract]   [Full Text] [Related]  

  • 67. [Trial of LL 505 dyspeptic states].
    Alary R; Savoye B; Dietsch R; Girard M
    J Med Lyon; 1970 Mar; 51(182):709-10. PubMed ID: 5476414
    [No Abstract]   [Full Text] [Related]  

  • 68. A CONTROLLED TRIAL OF A NEW AGENT ('LIBRAXIN') FOR DYSPEPSIA.
    ANDERSON TR
    N Z Med J; 1963 Oct; 62():482-4. PubMed ID: 14073067
    [No Abstract]   [Full Text] [Related]  

  • 69. Omeprazole and placebo have same long-term effect on dyspepsia.
    Lepsch M; Strayer SM
    J Fam Pract; 2003 Sep; 52(9):687-8. PubMed ID: 12967538
    [No Abstract]   [Full Text] [Related]  

  • 70. Omeprazole was effective in the short term for uninvestigated dyspepsia.
    Talley NJ
    ACP J Club; 2003; 138(3):70. PubMed ID: 12725625
    [No Abstract]   [Full Text] [Related]  

  • 71. Response to Marlicz et al.
    Moayyedi P; Lacy BE; Andrews CN; Enns RA; Howden CW; Vakil N
    Am J Gastroenterol; 2018 May; 113(5):781. PubMed ID: 29523865
    [No Abstract]   [Full Text] [Related]  

  • 72. Proton pump inhibitors for functional dyspepsia.
    Pinto-Sanchez MI; Yuan Y; Hassan A; Bercik P; Moayyedi P
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011194. PubMed ID: 29161458
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Proton pump inhibitors for functional dyspepsia.
    Pinto-Sanchez MI; Yuan Y; Bercik P; Moayyedi P
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011194. PubMed ID: 28271513
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug treatment of functional dyspepsia.
    Mönkemüller K; Malfertheiner P
    World J Gastroenterol; 2006 May; 12(17):2694-700. PubMed ID: 16718755
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pathogenesis and therapy for idiopathic dyspepsia.
    Tack J; Kindt S
    Curr Gastroenterol Rep; 2005 Dec; 7(6):437-44. PubMed ID: 16313872
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design.
    Madsen LG; Bytzer P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):365-72. PubMed ID: 15274674
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?
    Madsen LG; Wallin L; Bytzer P
    Aliment Pharmacol Ther; 2004 Aug; 20(4):423-30. PubMed ID: 15298636
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model.
    Madsen LG; Bytzer P
    Dig Dis; 2008; 26(3):237-42. PubMed ID: 18463442
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Identifying responders to acid suppression in dyspepsia using a random starting day trial.
    Bytzer P; Hansen JM; Rune S; Bonnevie O; Breinstrup H; Funch-Jensen P; Matzen P; Meineche-Schmidt V; Schaffalitzky De Muckadell OB
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1485-94. PubMed ID: 11069320
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Which dyspepsia patients will benefit from omeprazole treatment? Analysis of a Danish multicenter trial.
    Meineche-Schmidt V; Christensen E
    Am J Gastroenterol; 2000 Oct; 95(10):2777-83. PubMed ID: 11051347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.